CGC(Canopy Growth Corporation) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2022-03-31 | FY 截至 2023-03-31 | FY 截至 2024-03-31 | FY 截至 2025-03-31 | FY 截至 2026-03-31 |
|---|---|---|---|---|---|
| 营业收入 | $378.44M | $250.17M | $220.16M | $192.75M | $206.43M |
| 毛利润 | −$149.10M | −$47.69M | $59.93M | $56.97M | $50.53M |
| 营业利润 | −$810.50M | −$1.97B | −$169.46M | −$83.94M | −$117.25M |
| 净利润 | −$246.65M | −$2.46B | −$513.97M | −$364.63M | −$190.69M |
| 经营现金流 | −$434.22M | −$418.55M | −$208.90M | −$118.77M | −$46.28M |
| 自由现金流 | −$463.40M | −$425.39M | −$211.46M | −$126.52M | −$50.15M |
| 摊薄每股收益 | $-6.30 | $-53.07 | $-6.87 | $-3.39 | $-0.64 |